Stereotaxis, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on February 28, 2013, by Stereotaxis, Inc., a medical device company based in St. Louis, Missouri. The report primarily addresses significant changes in executive leadership and incorporates by reference the company's financial results for the fourth quarter and full year ended December 31, 2012, which were announced in a press release dated March 5, 2013.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release filed as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K.
Material Changes and Executive Departure
The most significant event reported is the resignation of Michael Kaminski, President and Chief Executive Officer. Key details include:
- Resignation Date: Effective April 12, 2013.
- Board Resignation: Mr. Kaminski will also resign from the Board of Directors on April 12, 2013.
- Interim Successor: William C. Mills III, Chairman of the Board, will serve as Interim CEO and Principal Executive Officer effective April 13, 2013.
- Background: Mr. Mills is an independent venture capitalist with over 32 years of experience in healthcare venture capital.
Compensation, Risks, and Contingencies
As part of the transition, the following arrangements were established for the departing CEO:
- Consulting Role: Mr. Kaminski will provide consulting and advisory services for 18 months (April 13, 2013, through October 13, 2014).
- Equity Vesting: Unvested restricted stock, options, and stock appreciation rights will continue to vest through October 13, 2014. Vested unexercised options remain exercisable until the earlier of their original expiration or October 13, 2014.
- Change of Control: Unvested equity awards will accelerate and become fully vested upon a change of control.
- Bonus Eligibility: Mr. Kaminski remains eligible for the Q1 2013 management bonus if performance criteria are met but is ineligible for bonuses thereafter.
- Restrictions: Confidentiality, non-competition, non-solicitation, and non-disparagement obligations remain in effect for two years post-resignation.
There are no disclosed related party transactions involving Mr. Mills exceeding $120,000 since January 1, 2010.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 5, 2013) for specific Q4 and full-year 2012 financial results, as they are not listed in this 8-K.
- Monitor the company's progress in appointing a permanent CEO to replace the interim leadership.
- Verify the impact of the leadership transition on the company's strategic direction and product development pipeline.
- Check for any subsequent filings regarding the search for a permanent CEO or changes to the Board composition.